This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Intuitive Surgical (ISRG) Preliminary Q4 Revenues Improve Y/Y
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter revenues reflect a strong demand in procedure volume as China recovers following the resurgence of COVID-19 in early 2023.
Integer Holdings (ITGR) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Integer Holdings' (ITGR) revenue growth in the fourth quarter is likely to have been boosted by continued strong customer demand for its products.
GE Healthcare (GEHC) Buys MIM Software to Boost Imaging Tools
by Zacks Equity Research
GE Healthcare (GEHC) is likely to enhance medical imaging capabilities and boost powerful AI solutions with the acquisition of MIM Software. Financial details are kept under cover.
Veradigm (MDRX) & MedAllies Partner for Better Care Decisions
by Zacks Equity Research
Veradigm's (MDRX) partnership with MedAllies is likely to gain access to a wider range of patient data and drive better treatment decisions.
Nevro's (NVRO) Preliminary Q4 Revenues Boosted by PDN Sales
by Zacks Equity Research
Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.
QIAGEN (QGEN) Gains From New Alliances Amid FX Headwind
by Zacks Equity Research
QIAGEN (QGEN) is progressing well with its testing menu expansion strategy, which is driving the company's growth.
SenesTech's (SNES) New Partnership to Broaden Evolve's Scope
by Zacks Equity Research
The collaboration with a global leader in irrigation solutions for sustainable agriculture aligns with SenesTech's (SNES) target to introduce Evolve to a broader audience.
PacBio (PACB) Preliminary Q4 Revenues Boosted by Revio Sales
by Zacks Equity Research
PacBio's (PACB) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its sequencing systems.
Inspire Medical (INSP) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Inspire Medical's (INSP) revenue growth in the fourth quarter is likely to have been boosted by improved operating leverage.
DexCom (DXCM) Preliminary Q4 Revenues Ride on Sensor Demand
by Zacks Equity Research
DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by strong demand for its CGM sensors across the globe. It delivers robust revenue guidance for 2024.
Fresenius Medical (FMS) Divests Businesses to Optimize Portfolio
by Zacks Equity Research
Fresenius Medical (FMS) streamlines for success with three key divestments in 2023. These divestments are likely to impact operating income by EUR 500 million in the fourth quarter.
Illumina (ILMN) Extends Partnership to Advance Cancer Test
by Zacks Equity Research
Illumina (ILMN) aims to work with other pharmaceutical industry leaders to enhance and expand the utility of its WGS MRD assay.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) led by solid prospects in the Diagnostic business and raised guidance.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.
Avanos (AVNS) Preliminary Q4 Revenues Dampened by Lower Sales
by Zacks Equity Research
Avanos' (AVNS) revenue growth in the fourth quarter is likely to have been dampened by lower HA pain relief injection product sales.
Veradigm's (MDRX) Acquires Koha Health to Solidify Market Presence
by Zacks Equity Research
Veradigm's (MDRX) acquisition of Koha Health will likely enhance its ability to deliver efficient revenue cycle services by incorporating Musculoskeletal Medicine specialty subject matter expertise.
Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Walgreens Boots (WBA) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Walgreens Boots' (WBA) comparable pharmacy sales in the fiscal first quarter benefited from higher branded drug inflation and strong execution in pharmacy services.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN) on robust testing volumes and strong solvency position.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Enovis (ENOV) to Strengthen Portfolio Via Its Latest Buyout
by Zacks Equity Research
Enovis' (ENOV) latest buyout is expected to expand its international scale with a complementary global customer base and product mix and improve efficiency with innovative manufacturing facilities.
Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Haemonetics (HAE) Up 11% in a Year: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) owing to its strategic focus on establishing leading positions in high-growth markets and raised guidance.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on strength in base business and strategic collaborations.